Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01452828 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetics and Safety Study in Subjects With Renal Impairment
A Phase 1 study, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01452828 is a Phase 1 study that has completed, run by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 24 participants.
The verdict
NCT01452828, a Phase 1 study, has completed, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the single dose pharmacokinetics (PK) and safety of TR701 FA in subjects with advance renal impairment.
Interventions
- DRUG TR-701 FA
- DRUG TR-701 FA single infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)18 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01452828
The ClinicalTrials.gov registry entry for NCT01452828 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TR-701 FA is the first listed.
NCT01452828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01452828 about?
NCT01452828 is a clinical study titled "A Pharmacokinetics and Safety Study in Subjects With Renal Impairment". The purpose of this study is to assess the single dose pharmacokinetics (PK) and safety of TR701 FA in subjects with advance renal impairment.
What is the current status of trial NCT01452828?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2011-10. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01452828?
The interventions under investigation include: TR-701 FA (DRUG), TR-701 FA single infusion (DRUG).
Who is sponsoring clinical trial NCT01452828?
This trial is sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.